S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
New AI Stock Payouts (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
New AI Stock Payouts (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
New AI Stock Payouts (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
New AI Stock Payouts (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
New AI Stock Payouts (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
New AI Stock Payouts (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
New AI Stock Payouts (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
New AI Stock Payouts (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Canadian autoworkers ratify new labor agreement with Ford
NASDAQ:INSY

INSYS Therapeutics (INSY) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.23
▼
$65,799,000.00
52-Week Range
N/A
Volume
N/A
Average Volume
9.52 million shs
Market Capitalization
$21.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

INSY stock logo

About INSYS Therapeutics (NASDAQ:INSY) Stock

Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.


INSY Stock News Headlines

August 18, 2023 | reuters.com
Insys founder Kapoor should repay $6 mln for failed legal defense, judge rules
July 28, 2023 | reuters.com
Doctor should face trial over Insys opioid kickbacks despite bankruptcy, US says
September 25, 2023 | Legacy Research (Ad)
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
May 11, 2023 | marketwatch.com
Global Infantile Spasm Treatment Market Production and Future Outlook 2031
May 2, 2023 | marketwatch.com
Synthetic Cannabinoid Market Key Players and Competitive Landscape till 2031
May 2, 2023 | marketwatch.com
Medical Cannabis Market Competitive Landscape, Top Growing Regions, Segmentations, and Leading Key Opportunity Forecast to 2031
April 27, 2023 | marketwatch.com
Dravet Syndrome Thereapeutics Market Growth by 2031
April 27, 2023 | marketwatch.com
Synthetic Cannabinoid Market Global Analysis 2023-2030
September 25, 2023 | Legacy Research (Ad)
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
April 25, 2023 | marketwatch.com
Infantile Spasm Treatment Market 2023 with Leading Players and Growth by 2030
April 14, 2023 | benzinga.com
REID COLLINS & TSAI LLP RECOVERS $175 MILLION SETTLEMENT FROM FORMER INSYS DIRECTORS IN OPIOID-RELATED LAWSUIT
April 5, 2023 | marketwatch.com
Infantile Spasm Treatment Market: Emerging Trends and Predication 2023-2028
March 29, 2023 | reuters.com
Enforcement trends and caution points in health care private equity investing
March 29, 2023 | marketwatch.com
Synthetic Cannabinoid Market New Ready Report Analysis 2028
March 27, 2023 | benzinga.com
Is Big Pharma Coming For Your Cannabis Business?
March 18, 2023 | marketwatch.com
2023 Infantile Spasm Treatment Market Supply-Demand Outlook, Regional Insights and Statistics, with Emerging Trends by 2030
March 15, 2023 | marketwatch.com
Infantile Spasms Therapeutics Market Intelligence Report 2023 to FFFF | Analysis of Growth, Share, Current Trends And Restraints
March 14, 2023 | marketwatch.com
Dravet Syndrome Thereapeutics Market Application, Product, Sales and Forecast 2023-2028
March 9, 2023 | marketwatch.com
Infantile Spasms Therapeutics Market Industry Size, Share, Trends, Growth Analysis and Forecast to 2028
March 4, 2023 | marketwatch.com
Review of Infantile Spasm Treatment Market 2023-2028 Latest Research Report
February 28, 2023 | benzinga.com
Century Therapeutics Stock (NASDAQ:IPSC), Quotes and News Summary
February 27, 2023 | marketwatch.com
Sublingual Sprays Market Research Report 2023-2029
February 26, 2023 | thestreet.com
Why Insys Therapeutics (INSY) Stock Is Plunging Today
February 2, 2023 | marketwatch.com
Fentanyl Market Size, Analysis, Global Leading Key Players, Forecast to 2028
January 30, 2023 | marketwatch.com
Synthetic Cannabinoid Market | Rising Sales of the Industry Are Set To Drive for Growth Prospects and Innovations | 2028
January 30, 2023 | marketwatch.com
Synthetic Cannabinoid Market Opportunities, Demand and Forecasts, 2023-2028 with Top Countries Data
January 26, 2023 | marketwatch.com
Infantile Spasm Treatment Market: Pronounce Growth by Regions 2023 | Business Strategies, Developments and Future Demand Forecast to 2028
See More Headlines
Receive INSY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INSYS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INSY Company Calendar

Last Earnings
5/10/2019
Today
9/25/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INSY
Previous Symbol
NASDAQ:NEOL
CUSIP
N/A
CIK
1516479
Web
www.insysrx.com
Phone
480-500-3127
Fax
N/A
Employees
226
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.39)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-124,510,000.00
Net Margins
-346.61%
Pretax Margin
N/A
Return on Equity
-1,430.37%
Return on Assets
-64.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.54
Quick Ratio
0.50

Sales & Book Value

Annual Sales
$82.08 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.58) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
74,570,000
Free Float
N/A
Market Cap
$21.71 million
Optionable
Optionable
Beta
3.21
10 Best Stocks to Own in 2023 Cover
10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Steven J. Meyer (Age 62)
    Exec. Chairman
  • Mr. Saeed Motahari (Age 53)
    CEO, Pres & Director
  • Mr. Andrew G. Long
    Chief Financial Officer
  • Dr. Danny L. Tuck
    Sr. VP of Quality Operations
  • Mr. Franc Del Fosse (Age 47)
    Sr. VP of Corp. Affairs

Key Competitors

View All Competitors













INSY Stock - Frequently Asked Questions

How were INSYS Therapeutics' earnings last quarter?

INSYS Therapeutics, Inc. (NASDAQ:INSY) released its earnings results on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.33. The specialty pharmaceutical company had revenue of $7.63 million for the quarter, compared to analyst estimates of $14.95 million. INSYS Therapeutics had a negative net margin of 346.61% and a negative trailing twelve-month return on equity of 1,430.37%. The business's revenue for the quarter was down 68.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.19) EPS.

When did INSYS Therapeutics' stock split?

INSYS Therapeutics shares split before market open on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly issued shares were issued to shareholders after the closing bell on Friday, March 28th 2014. An investor that had 100 shares of stock prior to the split would have 150 shares after the split.

What other stocks do shareholders of INSYS Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other INSYS Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), (MDVN) (MDVN) and NVIDIA (NVDA).

What is INSYS Therapeutics' stock symbol?

INSYS Therapeutics trades on the NASDAQ under the ticker symbol "INSY."

How much money does INSYS Therapeutics make?

INSYS Therapeutics (NASDAQ:INSY) has a market capitalization of $0.00 and generates $82.08 million in revenue each year. The specialty pharmaceutical company earns $-124,510,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis.

How many employees does INSYS Therapeutics have?

The company employs 226 workers across the globe.

How can I contact INSYS Therapeutics?

INSYS Therapeutics' mailing address is 1333 S. Spectrum Blvd Suite 100, Chandler AZ, 85286. The official website for the company is www.insysrx.com. The specialty pharmaceutical company can be reached via phone at 480-500-3127 or via email at insy@alpha-ir.com.

This page (NASDAQ:INSY) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -